U.S., Aug. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07143448) titled 'A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults' on Aug. 20.
Brief Summary: Phase 1b Study of HS235 Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of the Activin Signaling Inhibitor HS235 Added to Background Treatment in Adults with Pulmonary Arterial Hypertension (PAH)
Study Start Date: Oct., 2025
Study Type: INTERVENTIONAL
Condition:
Pulmonary Arterial Hypertension
Intervention:
BIOLOGICAL: HS235
Subcutaneous Injection
OTHER: Placebo
Subcutaneous Injection
Recruitment Status: NOT_YET_RECRUITING
Sponsor: 35Pharma Inc
Disclaimer: Curated by HT Syndication....